SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

This is a Phase II, prospective, single-arm exploratory clinical trial designed to evaluate the efficacy and safety of stereotactic body radiotherapy followed by ipilimumab N01 plus sintilimab in combination with nab-paclitaxel and gemcitabine in patients with locally advanced pancreatic cancer. Eligible patients will receive SBRT followed by sequential systemic therapy. The primary endpoint is progression-free survival, and secondary endpoints include overall survival, disease control rate, duration of response, objective response rate, and safety.

Trial Details

NCT ID

NCT07683221

Phase

PHASE2

Sponsor

Shandong Cancer Hospital and Institute

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy

Locations (sample)

Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

Participants voluntarily agree to participate in the study, sign the informed consent form, and are willing and able to comply with study procedure…
Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
Locally advanced unresectable pancreatic cancer without distant metastasis, confirmed by multidisciplinary team evaluation.
Age 18 to 75 years, inclusive.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →